



PerkinElmer Expands KRAS Oncology Drug Discovery Assays with New Ready-to-Use AlphaLISA Kits

7/28/2021

PDF Version

Will enable cancer researchers to accelerate identification and optimization of therapeutic leads by better decoding KRAS mutations present in 25% of tumors

WALTHAM, Mass. – July 28, 2021 – [PerkinElmer, Inc.](#), a global leader committed to innovating for a healthier world, today announced four new ready-to-use [AlphaLISA® KRAS kits](#), designed to help scientists better understand complex KRAS protein structures and mutations so they can more easily, quickly, and precisely identify potential new therapeutic candidates for a wide range of prevalent cancers. Researchers will now be able to choose between PerkinElmer's HTRF® or AlphaLISA assays to use the best methods for their individual labs.

The Company's AlphaLISA and HTRF kits are the first ready-to-use homogenous assays for KRAS/SOS1 inhibition analysis on the market. Prior to these offerings, labs looking to measure this inhibition in a no-wash format needed to develop their own assays, source their own proteins, and optimize assay conditions, which can be time and resource consuming. PerkinElmer's AlphaLISA and HTRF kits streamline workflows by offering fully validated kits to identify novel KRAS inhibitors in a no-wash format with no optimization necessary, and each kit comes with recombinant proteins, detection reagents, and assay buffers.

"KRAS mutations are present in approximately 25% of tumors, making them one of the most common gene mutations linked to cancer," said Alan Fletcher, senior vice president of life sciences and technology, PerkinElmer. "Because KRAS mutations are found in numerous types of cancer, from lung to colorectal to pancreatic cancers, it's a prime drug target. However, due to its complex protein structure, it's been quite difficult to research for many years. We're proud to help advance opportunities for researchers to learn more about KRAS mutations in the hopes of providing better treatment opportunities by bringing our AlphaLISA kits to market in this critical research space."

The addition of these assays further propels PerkinElmer's ability to provide end-to-end solutions for oncology researchers, which includes early stage drug discovery with assays, cell lines, microplates and plate readers, as well as later stage research with high-content screening, image analysis and management, automated liquid handling, and more. Learn more about PerkinElmer's cancer research solutions for genomics, cell-based assays, cellular imaging, in vivo imaging, and informatics [here](#).

Learn more about the new AlphaLISA KRAS assay kits [here](#) and about the Company's drug discovery technologies [here](#).

About PerkinElmer

PerkinElmer enables scientists, researchers, and clinicians to address their most critical challenges across science and healthcare. With a mission focused on innovating for a healthier world, we deliver unique solutions to serve the diagnostics, life sciences, food, and applied markets. We strategically partner with customers to enable earlier and more accurate insights supported by deep market knowledge and technical expertise. Our dedicated team of about 14,000 employees worldwide is passionate about helping customers work to create healthier families, improve the quality of life, and sustain the well-being and longevity of people globally. The Company reported revenue of approximately \$3.8 billion in 2020, serves customers in 190 countries, and is a component of the S&P 500 index. Additional information is available through 1-877-PKI-NYSE, or at www.perkinelmer.com.

Media Contact:

Adriana Howell

adriana.howell@perkinelmer.com

765-918-3070